NeuroTrials Research
404.851.9934
  • Home
  • Research Volunteers
    • Current Studies
    • Interested in Clinical Research?
    • What to Expect & FAQs
    • Refer a Friend
    • Tour our Research Site
  • Industry Professionals
    • Why Choose NTR?
    • Fact Sheet
  • Who We Are
    • News & Media
    • Clinical Investigators
    • Helpful Information
  • Contact Us

Dr. Rosenberg Discusses Sleep Issues & Clinical Research

3/3/2017

1 Comment

 
Picture

"If you have trouble falling asleep or staying asleep for three nights in a week, there is an issue."

​

In the latest issue of the Northside Neighbor, NeuroTrials CEO Dr. Russell Rosenberg discusses our work with sleep disorders in clinical research. NeuroTrials is working with volunteers who are willing to spend from one night to a few weeks at the facility for sleep analysis. The lab is always welcoming volunteers. Residents can earn $200 if they sign up, said Rosenberg, allowing them to develop medicines to help people have better sleep quality. But what does a patient have to say?
“I did the study initially just looking for a good night sleep. Doing the studies at NeuroTrials is totally for research. Once the drug (used during the study) is totally approved, it is feasible that you could ask a doctor to prescribe it,” said Debi Kimsey, a retired Atlanta resident who suffers from insomnia and found the research studies online and applied. “The reality is that the compensation for being a participant is good, and there is some satisfaction in knowing that you are working to help others find rest. The facility is top notch and the staff is awesome,” said Kimsey.

In addition to sleep disorders, NeuroTrials works with volunteers to study new medications effects on disorders like Parkinson's, Alzheimer's disease, migraines, and many more. View currently enrolling studies.

Read the full article from the Northside Neighbor.

If you are 55 or older with trouble sleeping, learn more about an insomnia study.

If you are 55 or older & a good sleeper, you may qualify for a healthy sleeper study.
1 Comment

Dr. Lacey Discusses Link Between Parkinson's Disease & Sleepiness

2/2/2017

603 Comments

 
Picture

Are you a Parkinson’s patient with trouble staying awake throughout the day? You are not alone.

According to the National Sleep Foundation, sleepiness during the day is seen in somewhere between 30-50% of patients with Parkinson’s disease. The origin of daytime fatigue in Parkinson’s patients has troubled researchers for some time in a “chicken or egg” scenario.

​Does Parkinson’s medication make patients sleepy, or does Parkinson’s itself lead to daytime drowsiness? As researchers continue to investigate the link between Parkinson’s & sleep, take a look at 5 early warning signs of Parkinson’s disease from the National Parkinson Foundation
.
​
  1. Tremor or Shaking. Have you noticed a slight shaking or tremor in your finger, thumb, hand, chin or lip? Does your leg shake when you sit down or relax? Twitching or shaking of limbs is a common early sign of Parkinson's disease.

  2. Small Handwriting. Has your handwriting suddenly gotten much smaller than in it was in the past? You may notice the way you write words on a page has changed, such as letter sizes are smaller and the words are crowded together. A sudden change in handwriting is often a sign of Parkinson's disease.

  3. Loss of Smell. Have you noticed you no longer smell certain foods very well? If you seem to have more trouble smelling foods like bananas, dill pickles or licorice, you should ask your doctor about Parkinson's disease.

  4. Trouble Sleeping. Do you thrash around in bed or kick and punch while you are deeply asleep? You might notice that you started falling out of bed while asleep. Sometimes, your spouse will notice, or will want to move to another bed. Sudden movements during sleep may be a sign of Parkinson's disease.

  5. Trouble Moving or Walking. Do you feel stiff in your body, arms or legs? Sometimes stiffness goes away as you move. If it does not, it can be a sign of Parkinson's disease. You might notice that your arms don't swing when you walk, or maybe other people have said you look stiff. An early sign might be stiffness or pain in your shoulder or hips. People sometimes say their feet seem 'stuck to the floor.'
    ​
For the complete list of Parkinson’s warning signs & more information, visit the National Parkinson Website.
If your sleep habits have changed since being diagnosed with Parkinson’s disease, you may qualify for a new research study examining a study drug for patients with Parkinson's disease experiencing excessive sleepiness. Qualified participants receive compensation for time & travel.

You may qualify if you:
  • are 35-80 years of age
  • are experiencing excessive sleepiness while on stable treatment for your Parkinson’s disease

For more information on this study, call NeuroTrials now at 404-851-9934 or visit the study page.
603 Comments

Trouble Sleeping? Options Are Available!

1/19/2017

33 Comments

 
Have you noticed as you age your quality of sleep declines? For many older adults, sleep problems just seem to come with the territory of aging. NeuroTrials Research is seeking to change that- we are currently enrolling for a research study for older adults with trouble sleeping. 

Dr. Russell Rosenberg recently sat down with Jennifer Leslie of 11Alive to share options available for adults looking for extra shut-eye. Jennifer also spoke with current NeuroTrials Research patient Debbie Kemsey about her experience in the clinical trial.

View the full 11Alive story.

For more information about this study, call 404-851-9934 or visit the study page.
33 Comments

Help Solve the Puzzle of Hypersomnia

9/13/2016

0 Comments

 
The Hypersomnia Foundation Board of Directors and volunteers worked for more than two years with physicians and researchers to create a hypersomnia-specific registry. That of hypersomnia patients is now ready for YOU to join, and the Hypersomnia Foundation will donate $50 to research for every person who completes the Hypersomnia Foundation Patient Registry Questionnaire during the month of September!

Why are registries so important?
Registries provide critical information, particularly about rare diseases. Uncovering that information makes a rare disease easier to study, increasing the probability that a treatment can be developed.
Typically, people with rare disorders are not geographically in the same place, making it difficult for scientists and medical professionals to gather information or samples from enough patients to study a rare disorder. However, a central registry helps to overcome that geography hurdle
​
Why would I take the time and use my limited energy to enroll in the registry and complete the questionnaires?
  • Your participation today will provide a brighter future for tomorrow. And don’t forget, it will help to fund research through the Hypersomnia Foundation Board of Director’s $50 contribution for every completed questionnaire. Your participation will also provide concrete help to researchers looking for answers.
  • The information about the central disorders of hypersomnolence will be housed in one location, accessible to any researcher anywhere in the world whose project is valid and approved by the Sanford Institutional Review Board.
  • One of the goals of a registry is to generate a hypothesis (a scientifically based idea) about which treatments might be effective. These hypotheses can assist the pharmaceutical industry (drug companies) to know which treatments to study in clinical trials.
  • Researchers who are interested in studying new treatments for hypersomnia can contact CoRDS, and CoRDS will then contact people who have checked the box during registry enrollment that they are interested in participating in additional research.

Visit the new Hypersomnia Foundation Registry page to complete the form.

If you are in the Atlanta-area & are interested in participating in a currently enrolling Idiopathic Hypersomnia study, visit our study landing page.
0 Comments

Homer Simpson: Our Next Research Patient?

9/25/2015

2 Comments

 
Picture
D'oh! It's not just the Duff beer & doughnuts lulling Homer Simpson to sleep. On this season's premiere of The Simpsons, we learn that Homer has been suffering from narcolepsy all these years. 

Ahead of Sunday's premiere, CNN sat down with NeuroTrials Research CEO Dr. Russell Rosenberg to discuss 
Homer's diagnosis, and what narcolepsy looks like for non-cartoon characters.

​"He's not the typical case, although the fact that he is now being identified as having narcolepsy does exemplify the fact that many people can go years and years without getting the proper diagnosis," Rosenberg said. "Who knows if they have a sleep specialist or sleep laboratory in Springfield?"


Typical patients start to show symptoms of narcolepsy when they are in their teens or 20s, although Rosenberg has seen patients as young as 2 years. Although Homer's age is difficult to pin down -- he hasn't aged much since the show debuted in December 1989 -- he's generally portrayed as being in his late 30s.

Along with excessive daytime sleepiness, people with narcolepsy usually have sleep attacks, or involuntarily episodes of slumber. These attacks can strike even when patients are doing something they enjoy, such as spending time with friends, Rosenberg said. Children may fall asleep in the middle of an activity at school, even if they are engaged in it.

About half of people with narcolepsy also have cataplexy, which causes them to lose muscle control when they feel strong emotions, such as when they're laughing, surprised or angry. Their facial muscles may droop or they may fall down. "This can be embarrassing (and) people try to blunt their emotions," Rosenberg said.

To read the full article, visit CNN.

Do you share a sleep disorder with Homer Simpson? Visit our Current Studies page to learn about research studies now enrolling for narcolepsy patients!


2 Comments

Groundbreaking Alzheimer's Research at NeuroTrials

7/10/2015

0 Comments

 
Picture

NeuroTrials Research is the home of a
 groundbreaking new study happening in Atlanta that hopes to stop the advancement of Alzheimer's disease, and doctors hope it could be the breakthrough so many people suffering from the disease have hoped for.




Primary investigator Dr. Michael Lacey & current patient Patti Eilbacher sat down with Atlanta's 11Alive to talk about the study this week. 


"We are looking at a compound that works in a different way than anything that's on the market right now," Dr. Lacey said. "This medication, as opposed to just treating the symptoms, is the first real medication that's gotten this far that deals specifically with the compounds or the agents that cause the disease to progress itself, so that's very exciting for us."

For full article details, visit the 11Alive site.


For more information on the study, visit the study page.
Picture
0 Comments

Dr. Rosenberg Appears on Atlanta NPR's "A Closer Look"

6/9/2015

0 Comments

 
Picture
People in Georgia are some of the sleepiest in the nation. That’s according to a study by the Centers for Disease Control and Prevention, which ranked Georgia as seventh in a listing of states with the worst sleeping habits.

The CDC found Georgia residents just don’t get enough shut-eye and that’s creating dangerous health risks. 

The CEO of NeuroTrials Research, Dr. Russell Rosenberg, said the amount and quality of sleep is a top indicator or a “vital sign” of good health.

“Georgians, in particular I think, are more at risk for obesity and there’s a higher prevalence of obesity in our state, which might account for some of that daytime sleepiness,” Rosenberg said.

To read the full article and listen to the full segment on the CDC's sleep study, click here.
0 Comments

NeuroTrials Research Joins Nationwide Alzheimer's Study

4/21/2015

0 Comments

 
Picture
A large national study is being conducted on an Alzheimer's drug candidate, and Atlanta-based NeuroTrials Research Inc. is the only trial site in Georgia currently enrolling patients. Dr. Michael Lacey serves as the study's primary investigator.

NeuroTrials is one of 50 locations across the United States participating in the NOBLE Study, a Phase-2 randomized, double blind, placebo controlled study on the potential of T-817MA, a neuroprotectant agent designed to protect against neuron loss. Neuroprotectants are used for central nervous system disorders including stroke and Parkinson's disease, but the NOBLE study is focusing on men and women with mild to moderate Alzheimer's disease.

A drug like the one being tested, which slows the progression of the disease rather than treating symptoms like other available treatments, has not been approved by the U.S. Food and Drug Administration since 2003.The study will enroll 450 people with mild to moderate Alzheimer's. Participants must be between the ages of 55 and 85, living in a community and not a nursing home, weigh no more than 220 pounds and have a study partner with at least 10 hours of contact per week. The must also have been on one of two Alzheimer's treatments, donepezil or rivastigimine, for at least six months.

Participants will be treated for about 14 months. For more information on the study & to see if someone you know may qualify, visit our study page.

Other trial sites include Georgetown University, Mount Sinai School of Medicine, Princeton University's Medical Institute and Columbia University.

Read the full article.

0 Comments
Forward>>

    Archives

    June 2018
    March 2018
    January 2018
    November 2017
    September 2017
    August 2017
    June 2017
    April 2017
    March 2017
    February 2017
    January 2017
    September 2016
    September 2015
    July 2015
    June 2015
    April 2015

    Categories

    All

    RSS Feed

NeuroTrials Research
1100 Johnson Ferry Road NE
Suite 420
Atlanta, GA 30342
404-851-9934